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Abstract.	
	
The	objective	of	 the	 research	was	 to	 study	 the	pathogenetic	 role	of	 the	
levels	 of	 endothelin-1	 (ET-1),	 tumor	 necrosis	 factor-alpha	 (TNF-alpha)	 and	 C-
reactive	 protein	 (CRP)	 in	 the	 development	 of	 endothelial	 dysfunction	 (ED)	 in	
patients	with	preserved	and	lost	renal	function.	
Materials	and	methods.	The	study	involved	86	patients:	Group	I	included	
42	patients	with	arterial	hypertension	and	chronic	heart	 failure	 (CHF)	 IIA	FC	 ІІІ;	
Group	 II	consisted	of	44	patients	with	terminal	chronic	kidney	disease	 (stage	V	
CKD)	 with	 concomitant	 CHF	 IIA	 FC	 ІІІ	 who	 were	 on	 treatment	 by	 outpatient	
program	hemodialysis	(HD).	
Results.	 In	 patients	 of	 Group	 II	 the	 levels	 of	 ET-1	 and	 inflammatory	
markers	 were	 significantly	 higher	 than	 those	 in	 the	 comparison	 and	 control	
groups	(p<0.001	and	p<0.001).	In	patients	of	Group	I	there	was	a	direct	moderate	
correlation	between	TNF-alpha	and	ET-1	 (r=0.48;	p<0.05)	and	between	CRP	and	
ET-1	 (r=0.56;	p<0.05).	 In	Group	 II,	the	relation	between	TNF-alpha	and	ET-1	was	
significantly	stronger	(r=0.58;	p<0.05);	between	the	levels	of	CRP	and	ET-1	it	was	
weaker	 (r=0.37,	 p<0.05).	 Increased	 levels	 of	 ET-1,	 TNF-±	 and	 CRP	 affected	 the	
development	of	ED	in	both	groups.	
Conclusions.	It	was	found	that	CRP	 levels	of	TNF-alpha,	ET-1	 in	patients	
on	HD	were	significantly	different	from	the	same	data	in	patients	with	preserved	
renal	 function,	 which	 is	 clearly	 associated	 with	 more	 pronounced	 signs	 of	
inflammation	and	ED	in	a	cohort	of	dialysis	patients.	The	impact	of	TNF-±	in	the	
development	of	ED	in	both	groups	was	proved.	Despite	the	higher	level	of	CRP	in	
patients	with	stage	V	CKD	being	corrected	by	HD	with	CHF,	this	biomarker	had	
less	 impact	on	 the	prognosis	of	 ED	 than	 in	 the	 general	population	of	patients	
with	CHF.	
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Chronic	heart	failure	(CHF)	occupies	the	first	place	among	all	cardiovascular	diseases	by	the	
rate	 of	 increase	 in	 incidence.	 Nowadays,	 the	 prevalence	 of	 this	 syndrome	 constitutes	 1-9%,	 the	
incidence	of	CHF	 increases	with	age	and	reaches	10-28%	after	the	age	of	65	 [2,	8].	The	prevalence	
of	CHF	is	much	higher	in	a	population	of	patients	with	terminal	chronic	kidney	disease	(CKD)	who	
are	 on	 hemodialysis	 (HD).	 Thus,	 CHF	 is	 diagnosed	 in	 almost	 one	 third	 of	 patients	 on	 HD	 [10].	
Endothelium	of	blood	 vessels	 intima	 is	 important	 in	 the	pathogenesis	of	CHF	development	 and	
progression.	 It	performs	barrier,	secretory,	homeostatic	 functions	and	plays	an	 important	role	 in	
the	processes	of	inflammation	and	remodeling	of	the	cardiovascular	system.	Endothelial	cells	are	
sensitive	 to	various	damaging	 factors	such	as	homeostasis	disorders,	 increased	concentration	of	
free	 radicals,	 cholesterol	 and	 inflammatory	mediators	under	 the	 influence	of	which	 endothelial	
dysfunction	 (ED)	 may	 develop	 being	 caused	 by	 an	 imbalance	 between	 substances	 providing	
vascular	tone	and	homeostasis	of	endothelium	processes	[4,	5,	13].	Under	physiological	conditions,	
the	secretion	of	vasoconstrictors	(angiotensin	II,	endothelin-1,	free	radicals,	thromboxane	A2)	and	
vasodilators	 (nitric	oxide,	hyperpolarizing	 relaxing	 factor,	prostacyclin	 I2)	 is	balanced.	However,	
this	 balance	 is	 disrupted	 with	 a	 predominance	 of	 vasoconstrictor	 reactions	 accompanied	 by	
increased	vascular	tone	and	 local	spasm	under	the	 influence	of	various	risk	factors.	Activation	of	
inflammatory	mediators	C-reactive	protein	(CRP)	and	tumor	necrosis	factor-alpha	(TNF-alpha)	are	
closely	related	to	oxidative	stress	and	ED.	According	to	many	researchers,	 long-term	exposure	to	
damaging	 factors	 leads	 to	 a	 gradual	 deterioration	 and	 distortion	 of	 vasodilation	 compensatory	
mechanisms.	 Thus,	 endothelium	 launches	 mechanisms	 of	 vasoconstriction	 and	 proliferation	 in	
response	 to	a	normal	 stimulus	 [1,	4,	5,	13].	Among	 the	endothelium-dependent	vasoconstrictors	
endothelin-1	(ET-1)	draws	the	attention	of	various	scientists	[1,	3,	6,	7,	11].	The	main	properties	of	
ET-1	 are	 its	 ability	 to	 affect	not	only	 the	 vascular	 tone	 causing	 vasoconstriction	 stable,	but	 also	
myocardial	 contractile	 function,	 the	 value	 of	 preload	 and	 afterload,	 platelet	 aggregation	 and	 to	
stimulate	the	development	of	myocardial	hypertrophy.	ED	is	a	characteristic	feature	accompanying	
CHF.	Many	studies	have	found	that	 increased	 levels	of	CRP	and	TNF-alpha	 in	blood	serum	are	an	
independent	predictor	of	CHF	progression	 [1,13,14].	However,	 the	 impact	of	 these	 inflammatory	
mediators	on	ED	severity	and	CHF	development	in	patients	requiring	replacement	therapy	is	poorly	
studied.		
The	objective	of	 the	 research	was	 to	determine	 the	pathogenetic	 role	of	ET-1,	TNF-alpha	
and	CRP	 in	patients	with	 stage	V	CKD	with	 concomitant	CHF	 requiring	HD	and	 in	patients	with	
essential	arterial	hypertension	(AH)	with	CHF	and	to	define	the	impact	of	end-stage	kidney	disease	
on	indicators	of	endothelial	dysfunction.	
	
Materials	and	methods	of	the	research		
The	 study	 involved	 86	 patients:	 Group	 I	 included	 42	 patients	 with	 AH	 and	 CHF	 IIA	 FC	 ІІІ	
(NYHA)	who	underwent	hospital	treatment	in	the	therapeutic	department	of	the	University	Clinic	
of	 IFNMU;	 Group	 II	 consisted	 of	 44	 patients	 with	 chronic	 kidney	 disease	 (stage	 V	 CKD)	 with	
concomitant	CHF	IIA	FC	ІІІ	(NYHA)	who	underwent	treatment	by	outpatient	program	hemodialysis	
(HD)	in	the	Department	of	Extracorporeal	Detoxification	Methods	and	Chroniodyalisis	at	the	Ivano-
Frankivsk	Regional	Clinical	Hospital	and	 in	Nephrology	and	Dialysis	Center	at	the	Kalush	Central	
District	Hospital.	The	average	age	of	the	patients	constituted	50.8	 ±	5.85,	median	of	HD	treatment	
duration	was	(3.58	±	1.32)	years.	The	examined	patients	included	49	(57%)	men	and	37	(43%)	women.	
Control	group	consisted	of	20	apparently	healthy	individuals.			
HD	was	performed	 to	patients	according	 to	 the	standard	program	 (3	 times	a	week	 for	4-5	
hours)	 on	 Innova	 devices	 of	 “Gambro”	company	 (Sweden)	using	a	semi-synthetic	 dialyzers	 and	
bicarbonate	buffer.	Provided	dialysis	dose	(eKt/V	ratio)	constituted	at	least	1.3.		
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Patients	with	severe	heart	rhythm	disorders,	poorly	controlled	diabetes	were	excluded	from	
the	research	as	well	as	patients	who	were	on	outpatient	HD	no	more	than	one	year,	eKt	/	V	ratio	
below	1.3,	hemoglobin	90	GM/DL.		
In	addition	 to	 full	blood	count	and	biochemical	blood	assay,	diurnal	variations	of	arterial	
blood	 pressure	 (ABP)	 were	 determined	 in	 all	 patients	 by	 means	 of	 24-hour	 blood	 pressure	
monitoring.	 The	 clinical	 condition	 of	 the	 patient	 was	 assessed	 by	 total	 points	 according	 to	 the	
rating	 scale	 of	 clinical	 state	 (Yu.V.	 Marieiev,	 2000)	 and	 6-minute	 walking	 test	 was	 conducted	 in	
order	to	clarify	the	functional	class	of	CHF	(according	to	NYHA	criteria).		CRP	level	was	determined	
with	 the	use	of	panel	according	 to	 semiquantitative	method	of	 latex	particle	agglutination	 “CRP	
Latex	Agglutination	Test”	 (Granum,	scientific	and	production	 laboratory	Ltd,	Ukraine).	TNF-alpha	
was	determined	on	reader	PR2100	 (Sanofi	diagnostics	Pasteur,	France)	using	a	set	of	“alpha-TNF-
EIA-Best”	(private	limited	company	“Vector-Best”,	Russia).	For	the	study	of	endothelial	dysfunction,	
the	 level	 of	 ET-1	 in	 serum	 was	 determined	 by	 enzyme-linked	 immunosorbent	 assay	 using	
“Biomedica”	kit	(Austria)	on	Stat-Fax	303	+	analyzer.	All	patients	participating	in	the	study	signed	
informed	consent.	
Statistical	processing	of	 the	data	was	performed	using	“Statistica	8.0	for	Windows”	taking	
into	account	the	test	for	normal	distribution	with	the	use	of	the	Kolmogorov-Smirnov	test.	In	case	
of	 normal	 distribution,	 mean	 values	 (M)	 and	 mean	 error	 of	 arithmetical	 average	 (m)	 as	 well	 as	
standard	deviation	(SD)	were	estimated.	Student’s	t-test	was	used	to	compare	the	average	values	of	
two	independent	samples.	Median	and	interquartile	range	(25%	and	75%)	were	used	in	case	of	non-
compliance	of	 the	normal	distribution	 law	 for	description	of	 the	 features.	Nonparametric	Mann–
Whitney	U	 test	 was	 applied	 for	 comparative	 analysis.	 Correlation	 relationship	 was	 investigated	
according	to	Pearson	method	(normal	distribution)	and	Spearman	(in	case	of	the	absence	of	normal	
distribution).	The	difference	was	considered	statistically	significant	at	p<0.05.		
	
Results	of	the	research	and	their	discussion		
Analysis	of	clinical	performance	and	laboratory	characteristics	(Table	1)	found	that	anemia	
symptoms	were	detected	in	both	research	groups,	however,	they	were	more	significant	in	the	group	
of	dialysis	patients.	Thus,	indices	of	hemoglobin	and	the	number	of	red	blood	cells	were	1.13	and	
1.21	times	below	normal	in	Group	I	of	patients.	Deviations	of	the	studied	indices	were	1.32	and	1.37	
times	(p<0.05)	below	normal	in	Group	II.		
	
Table	1	
Clinical	performance	and	laboratory	characteristics	of	the	patients	
Indices	 Control	
n=20	
Group	І		
(AH	with	CHF)	
n=42	
Group	ІІ		
(V	stage	CKD,	on	HD	
with	CHF)	
n=44	
Sex	(M/W)	 11/9	 23/19	 26/18	
Age,	years	 37.8±4.37	 54.6±5.47	 49.1±6.12	
AH	duration,	years	 -	 7.8±2.42	 6.7±0.87	
HD	treatment,	years	 -	 -	 3.58±1.32	
Hemoglobin,	GM/DL	 127.3±5.13	 112.4±4.16*	 96.4±3.07***ˆ ˆ	
Erythrocytes,	10¹²/l	 4.68±0.34	 3.89±0.09	 3.41±0.64*	
Leukocytes,	10⁹/l	 5.1±0.47	 7.2±0.13	 7.6±0.15	
Erythrocyte	sedimentation	
rate,	mm/h	
6.88±2.13	 7.23±1.43	 14.4±1.25**ˆ ˆˆ	
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Total	protein,	g/l	 73.1±3.84	 63.3±3.56*	 58.4±2.47**	
Albumins,	g/l	 52.2±3.21	 44.2±1.57*	 39.3±1.65**	
Total	cholesterol,	mmol/L	 4.17±1.11	 5.7±0.97	 6.3±1.12	
Urea,	mmol/L	 6.3±0.19	 7.1±0.24*	 14.3±1.15***ˆ ˆˆ	
Urea	after		dialysis	 -	 -	 7.8±0.23*	
Creatinine,	mcmol/l	 74.8±3.53	 103.1±5.3	 792.2±40.4***ˆ ˆˆ	
Creatinine	after		dialysis	 -	 -	 178.2±8.41***ˆ ˆˆ	
Body	mass	index,	kg/m²	 23.7±1.19	 28.7±1.14***	 27.1±1.07**	
Systolic	blood	pressure,	
millimeter	of	mercury	
124.2±4.68	 154.3±7.41*	 151.3±6.33*	
Diastolic	blood	pressure,	
millimeter	of	mercury	
81.4±2.52	 98.2±4.79*	 96.4±5.13*	
Note.	*	-	р<0.05;	**	-	р<0.01;	***	-	р<0.001;	in	comparison	with	the	control	group.	ˆ	-	р<0.05;	ˆˆ	-	
р<0.01;	ˆˆˆ	-	р<0.001;	in	comparison	between	Group	I	and	Group	II.		
	
The	significant	decrease	in	albumin	in	the	two	research	groups	comes	under	notice.	Indices	
of	 nitrogen	 metabolism	 were	 within	 normal	 range	 in	 patients	 of	 Group	 I	 whereas	 a	 significant	
increase	 in	 these	 data	 was	 observed	 in	 the	 group	 of	 dialysis	 patients	 even	 after	 adequate	 HD	
session	(р<0.001).	
In	 order	 to	 define	 vascular	 endothelium	 functions	 we	 studied	 the	 levels	 of	 ET-1.	 Many	
scientists	consider	 its	 increased	concentration	 to	be	associated	with	ED	 [7,	11].	The	 levels	of	CRP	
and	 TNF-alpha	 were	 determined	 in	 all	 patients	 of	 Group	 I	 and	 Group	 II	 (Table	 2).	 The	 obtained	
results	 implied	 that	 the	 levels	 of	 ET-1	 and	 inflammatory	 markers	 were	 significantly	 higher	 in	
patients	of	Group	II	in	comparison	with	the	control	group	and	the	comparison	group	(p<0.001	and	
p<0.001).	We	 consider	 the	 increase	 in	 these	markers	 in	patients	on	HD	 to	be	 caused	by	 chronic	
inflammation	and	uraemic	intoxication.		
	
Table	2	
The	level	of	CRP,	ET-1	and	TNF-alpha	in	blood	serum	in	the	control	group	and	comparison	
group	
Parameters	 Control	
n=20	
Group	І		
(AH	with	CHF)	
n=42	
Group	ІІ		
(V	stage	CKD,	on	HD	
with	CHF)	
n=46	
TNF-alpha,	pg/ml	 23.6±3.62	 63.2±12.29***	 103.5±25.61***ˆ ˆˆ	
ET-1,	pg/ml	 5.3±0.32	 9.7±1.37**	 12.01±1.36***ˆ ˆˆ	
CRP,	mg/l	 6	[0;6]	 9.0	[3.0;24]**	 24.0	[12;24]***ˆ ˆˆ	
Note.	*	-	р<0.05;	**	-	р<0.01;	***	-	р<0.001;	in	comparison	with	the	control	group.	ˆ	-	р<0.05;	ˆˆ	-	
р<0.01;	ˆˆˆ	-	р<0.001;	in	comparison	between	Group	I	and	Group	II.		
	
The	difference	between	the	studied	parameters	is	clearly	presented	in	the	form	of	box	plot	
(Fig.	1-3).	Increase	in	inflammatory	mediators	and	endothelial	vasoconstrictor	factor	in	both	groups	
of	 patients	 may	 indicate	 may	 indicate	 a	 significant	 part	 of	 these	 biological	 substances	 in	 CHF	
development	and	progression	[4,5,13].		
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Fig.	1.	Box	plot	of	ET-1	level	in	examined	groups	of	patients	with	CHF	
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Fig.2.	Box	plot	of	TNF-α	level	in	examined	groups	of	patients	with	CHF		
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Fig.3.	Box	plot	of	CRP	level	in	examined	groups	of	patients	with	CHF	
	
Literature	data	provide	information	about	the	relationship	of	ET-1	with	CHF	functional	class	
[3,	9].	However,	as	it	follows	from	our	research,	when	CHF	functional	class	was	the	same	in	patients	
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of	both	research	groups,	this	marker	was	significantly	higher	 in	patients	on	HD	being	apparently	
associated	with	more	severe	ED	in	this	cohort	of	examined	patients.		
Recent	 studies	have	 found	a	 relation	between	 the	 level	of	TNF-alpha	and	CHF	 stage,	but	
such	 studies	 usually	 do	 not	 include	 patients	 who	 require	 replacement	 therapy	 [4].	 However,	
analyzing	the	data	obtained	in	our	research,	the	levels	of	these	inflammatory	markers	in	patients	
on	 HD	 were	 much	 higher	 than	 in	 patients	 with	 preserved	 renal	 function,	 in	 spite	 of	 the	 same	
functional	class	of	CHF	(Fig.	2).		
High	level	of	CRP	in	the	group	of	dialysis	patients	may	be	provoked	by	chronic	inflammation,	
which	is	an	essential	sign	in	case	of	the	terminal	uremia	[1].		
Having	analyzed	the	correlation	matrix,	a	direct	moderate	correlation	between	the	level	of	
TNF-alpha	and	CRP	 in	both	research	groups,	but	this	correlation	was	much	stronger	 in	the	group	
of	dialysis	patients	 (r=0.52;	p<0.05	and	r=0.65;	p<0.05,	respectively)	 (Fig.4	and	Fig.5).	The	obtained	
results	are	in	agreement	with	the	literature	data	concerning	the	relationship	of	these	inflammatory	
markers	[12,14].		
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Fig.4.	Correlation	between	CRP	and	TNF-α	level	in	patients	of	Group	I		
	
Increase	 in	 CRP	 and	 TNF-alpha	 is	 well	 known	 to	 be	 an	 independent	 predictor	 of	
cardiovascular	 events	 [4].	 Correlation	 analysis	 between	 these	 markers	 and	 ET-1	 level	 was	
performed	to	study	the	value	of	these	indices	in	the	development	of	ED	(Fig.	6	–	Fig	9).	
Direct	 moderate	 correlation	 between	 TNF-alpha	 and	 ET-1	 (Fig.	 8)	 (r	 =	 0.48;	 p<0.05)	 and	
between	CRP	and	ET-1	(Fig.	6)	(r	=	0.56,	p<0.05)	was	established	in	Group	I.	In	Group	II,	the	relation	
between	TNF-alpha	and	ET-1	(Fig.	9)	was	significantly	stronger	(r=0.58;	p<0.05);	between	the	levels	
of	CRP	and	ET-1(Fig.	7)	it	was	weaker	(r=0.37,	p<0.05).		
Established	 correlation	 between	 the	 level	 of	 TNF-alpha	 and	 ET-1	 in	 both	 study	 groups	
indicates	 that	 the	 simultaneous	 increase	 in	 these	 markers	 is	 a	 significant	 predictor	 of	 ED	 and	
cardiovascular	complications	in	patients	with	CHF	regardless	of	renal	function.	Since	ET-1	causes	
endothelium-dependent	vasoconstriction,	vessel	constriction	provokes	the	synthesis	of	TNF-alpha	
which	 affects	 the	 increase	 of	 ET-1indirectly	 through	 CRP.	 Thus,	 a	 “vicious	circle”	of	pathogenic	
changes	is	formed	leading	to	a	disease	progression.	At	the	same	time,	though	increase	in	CRP	level	
in	 the	 blood	 of	 patients	 on	 HD	 is	 indisputable	 factor	 of	 CHF	 progression,	 it	 may	 predict	 ED	
development	to	a	lesser	extent	in	this	population.	
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Fig.	5.	Correlation	between	CRP	and	TNF-α	level	in	patients	of	Group	II		
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Fig.	6.	Correlation	between	CRP	and	ET-1	level	in	patients	of	Group	I	
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Fig.	7.		Correlation	between	CRP	and	ET-1	level	in	patients	of	Group	II	
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Fig.8.	Correlation	between	TNF-α	and	ET-1	level	in	patients	of	Group	I	
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Fig.9.	Correlation	between	TNF-α	and	ET-1	level	in	patients	of	Group	II	
	
Conclusions	
1. CRP	levels	of	TNF-alpha,	ET-1	in	patients	on	HD	were	found	to	be	significantly	different	
from	 the	 same	 data	 in	 patients	 with	 preserved	 renal	 function,	 which	 is	 clearly	
associated	with	more	pronounced	signs	of	inflammation	and	ED	in	a	cohort	of	dialysis	
patients.	
2. The	impact	of	TNF-±	in	the	development	of	ED	in	both	groups	was	proved.	
3. Despite	the	higher	level	of	CRP	in	patients	with	stage	V	CKD	being	corrected	by	HD	with	
CHF,	 this	 biomarker	 had	 less	 impact	 on	 the	 prognosis	 of	 ED	 than	 in	 the	 general	
population	of	patients	with	CHF.	
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